Efficacy of Paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer

BACKGROUND: Later line chemotherapy (≥2nd lines) such as Docetaxel or immunotherapy is frequently used. As the life expectancy of lung cancer patients is getting longer, we need to provide more treatment options. Other treatment options are not well documented except for Doxetaxel and immunotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Yen-Han, Shih, Jen-Fu, Chao, Heng-Sheng, Chen, Yuh-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2019
Materias:
Drugs and Devices
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764356/
https://www.ncbi.nlm.nih.gov/pubmed/31579626
http://dx.doi.org/10.7717/peerj.7767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764356/
https://www.ncbi.nlm.nih.gov/pubmed/31579626
http://dx.doi.org/10.7717/peerj.7767

Ejemplares similares